Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ERA 223: A phase 3 trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone-predominant metastatic castration-resistant prostate cancer (mCRPC)

Date

19 Oct 2018

Session

Proffered paper session - Genitourinary tumours, prostate

Presenters

Matthew Smith

Authors

M.R. Smith1, C.C. Parker2, F. Saad3, K. Miller4, B. Tombal5, Q.S. Ng6, M. Bögemann7, V. Matveev8, J.M. Piulats9, L.E. Zucca10, A. Heidenreich11, Y. Kakehi12, A. Zhang13, H. Krissel14, J. Shen15, V. Wagner16, C. Higano17

Author affiliations

  • 1 Department Of Oncology, Massachusetts General Hospital, 2114 - Boston/US
  • 2 Department Of Urology, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, SM2 5PT - Sutton/GB
  • 3 Department Of Urology, University of Montreal Hospital Center (CHUM), H2X 3J4 - Montreal/CA
  • 4 Department Of Medical Oncology, Charité Berlin, Berlin/DE
  • 5 Department Of Urology, Cliniques Universitaires St. Luc, 1200 - Brussels/BE
  • 6 Division Of Medical Oncology, National Cancer Centre Singapore, Singapore/SG
  • 7 Department Of Clinical Oncology (urology), University of Muenster Medical Center, Muenster/DE
  • 8 Department Of Urology, N.N. Blokhin Cancer Research Center, Moscow/RU
  • 9 Department Of Medical Oncology, Catalan Cancer Institute, Barcelona/ES
  • 10 Department Of Medical Oncology, Barretos Cancer Hospital, Barretos/BR
  • 11 Department Of Urology, University Hospital Cologne, Cologne/DE
  • 12 Department Of Urology, Kagawa University, Kagawa/JP
  • 13 Oncology, Bayer HealthCare Pharmaceuticals, Whippany/US
  • 14 Oncology, Bayer AG, Berlin/DE
  • 15 Clinical Statistics, Bayer HealthCare Pharmaceuticals, Whippany/US
  • 16 Oncology, Bayer Consumer Care AG, Basel/CH
  • 17 Department Of Medical Oncology, University of Washington and Fred Hutchinson Cancer Research Center, Seattle/US
More

Resources

Background

Abiraterone acetate and prednisone/prednisolone (AAP) improves progression-free survival and overall survival (OS) in men with mCRPC. Ra-223 increases OS and decreases symptomatic skeletal events (SSEs) in men with mCRPC and bone metastases. We evaluated concurrent treatment with AAP and Ra-223.

Methods

This phase 3, double-blind, placebo (PBO)-controlled trial randomised asymptomatic/mildly symptomatic men with chemotherapy-naïve mCRPC and bone metastases in a 1:1 ratio of AAP + Ra-223 or AAP + PBO. Bone health agents (BHAs [bisphosphonates or denosumab]) were only allowed in pts receiving them at baseline. The primary endpoint was SSE-free survival (SSE-FS).

Results

806 pts were randomised (401 to AAP + Ra-223; 405 to AAP + PBO); 39% and 42% of pts were receiving BHAs at baseline in the AAP + Ra-223 and AAP + PBO arms, respectively. The trial was unblinded early after more fractures and deaths were observed in the AAP + Ra-223 arm. All pts had completed study-specified Ra-223/PBO treatment prior to unblinding. At the primary analysis, median SSE-FS was 22.3 mo (95% CI 20.4−24.8) with AAP + Ra-223 and 26.0 mo (95% CI 21.8−28.3) with AAP + PBO (HR 1.122, 95% CI 0.917−1.374; p=0.2636). Median OS was 30.7 mo (95% CI 25.8−not estimable) with AAP + Ra-223 and 33.3 mo (95% CI 30.2−41.1) with AAP + PBO (HR 1.195, 95% CI 0.950−1.505; p=0.1280). Other secondary/exploratory endpoints are shown in the Table. Fractures occurred in 29% and 11% of pts in the AAP + Ra-223 and AAP + PBO arms, respectively. In pts receiving BHAs, 15% and 7% experienced a fracture in the AAP + Ra-223 and AAP + PBO arms, respectively, vs 37% and 15% without BHAs.

AAP + Ra-223
N=401
AAP + PBO
N=405
HR (95% CI)
Additional secondary endpoints
rPFS (central review), median (95% CI), months 11.2 (9.1–11.8) 12.4 (10.8–14.5) 1.152 (0.960–1.383)
Time to cytotoxic chemotherapy, median (95% CI), months 29.5 (26.5–35.7) 28.5 (23.7–NE) 1.033 (0.816–1.308)
Time to opiate use for cancer pain, median (95% CI), months 19.0 (14.4–23.2) 22.6 (18.0–25.7) 1.126 (0.921–1.378)
Exploratory endpoints
Overall confirmed PSA response, n/N (%) 287/396 (72) 267/401 (67)
Time to PSA progression, median (95% CI), months 9.6 (8.2–10.8) 9.0 (7.9–10.1) 0.937 (0.792–1.108)
Overall confirmed ALP response, n/N (%) 218/398 (55) 104/402 (26)
Time to ALP progression, median (95% CI), months 7.4 (7.1–7.9) 6.8 (5.3–8.4) 1.083 (0.918–1.276)
Time to deterioration in health-related quality of life*,
median (95% CI), months
9.5 (6.9–12.0) 10.5 (8.3–13.0) 1.079 (0.865–1.345)
*As reported in the safety population (AAP + Ra-223 N=392, AAP + PBO N=394) using the NCCN-FACT FPSI-17 physical disease-related symptoms subscale score measured during the treatment period. ALP: alkaline phosphatase; NE: not estimable; PSA: prostate-specific antigen; rPFS: radiological progression-free survival.

Conclusions

Concurrent AAP + Ra-223 treatment did not improve SSE-FS or OS and led to a higher fracture rate. Based on these results, we do not recommend Ra-223 in combination with AAP.

Clinical trial identification

NCT02043678

Editorial Acknowledgement

Medical writing support was provided by Michael Sheldon, PhD, of Scion, London, UK, funded by Bayer

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings